secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001581280-26-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience preliminary Q1 FY2026 revenue ~$103.7M, up 17% YoY, ahead of guidance
--------------------------------------------------------------------------------

- Preliminary Q1 FY2026 revenue ~$103.7M (+/- $0.2M), 17% YoY growth, above guidance of $100-101M.
- DNA Synthesis & Protein Solutions revenue $51.1M (+/- $0.1M), up 27% YoY.
- NGS Applications revenue $52.6M (+/- $0.1M), ahead of guidance; excluding one customer transition, NGS grew 18% YoY.
- Full Q1 financial results to be reported on Feb 2, 2026, before market open.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000158128026000012/0001581280-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000158128026000012/twist-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001581280-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer